InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,308.15
(
1.17%
)
US TECH 100
18,138.40
(
1.69%
)
Dow Jones
39,908.00
(
0.88%
)
Brent Oil
82.95
(
0.35%
)
Bitcoin
65,825.00
(
-0.66%
)
Post# of 251828
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: None

Monday, 12/12/2016 1:24:01 AM

Monday, December 12, 2016 1:24:01 AM

Post# of 251828
OPHT - Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration
- No benefit observed upon addition of Fovista® to monthly Lucentis® regimen for the treatment of wet age-related macular degeneration -
- Conference Call and Webcast Today, December 12, 2016 at 8:30 a.m. ET -

http://investors.ophthotech.com/releaseDetail.cfm?ReleaseID=1003651
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up